Skip to main content

Table 4 Presence and relative magnitude of antibodies to P. falciparum and P. vivax antigens by age in a subset of 264 participants

From: Household and individual level risk factors associated with declining malaria incidence in Meghalaya, India: implications for malaria elimination in low-endemic settings

Antigen/

Antibody

Number of seropositive individuals

n (% of age category)

Relative magnitude of response*

Relative MFI value (IQR)

Age (1–7 years)

(N = 77)

Age (8–17 years)

(N = 72)

Age (≥ 18 years)

(N = 115)

P-value^

Age (1–7 years)

Age (8–17 years)

Age (≥ 18 years)

P-value¶

PfAMA1

30 (39.0%)

31 (43.1%)

98 (85.2%)

< 0.001

1.21 (1.10–1.57)

1.52 (1.24–1.69)

4.83 (1.92–13.64)

< 0.001

PfEBA140

13 (16.9%)

13 (18.1%)

63 (54.8%)

< 0.001

2.40 (1.53–3.38)

1.86 (1.50–2.89)

2.22 (1.52–4.60)

0.720

PfEBA175

9 (11.7%)

12 (16.7%)

82 (71.3%)

< 0.001

1.09 (7.35–1.79)

1.86 (1.19–2.43)

3.74 (2.15–7.45)

< 0.001

PfEBA181

6 (7.8%)

15 (20.8%)

69 (60.0%)

< 0.001

1.46 (1.25–2.75)

1.35 (1.19–2.90)

3.65 (1.97–6.10)

0.001

PfEtramp5.Ag1

12 (15.6%)

16 (22.2%)

67 (58.3%)

< 0.001

1.34 (1.20–1.94)

1.49 (1.12–1.69)

2.25 (1.48–4.20)

0.001

PfGlurp.R2

5 (6.5%)

11 (15.3%)

60 (69.6%)

< 0.001

1.77 (1.42–2.17)

1.38 (1.08–3.37)

4.72 (1.94–10.78)

0.007

PfHSP40.Ag1

9 (11.7%)

9 (12.5%)

57 (49.6%)

< 0.001

1.43 (1.15–2.14)

2.05 (1.11–2.15)

1.95 (1.43–2.99)

0.077

PfMSP119

4 (5.2%)

6 (8.3%)

91 (79.1%)

< 0.001

1.50 (1.12–2.29)

1.13 (1.04–1.25)

5.45 (2.70–16.35)

< 0.001

PfMSP2_Ch150

3 (3.9%)

4 (5.6%)

45 (39.1%)

< 0.001

1.01, 1.02, 1.39

1.11 (1.09–1.88)

1.49 (1.22–2.93)

0.058

PfMSP2_Dd2

23 (29.9%)

10 (13.9%)

68 (59.1%)

0.002

2.70 (1.36–16.19)

1.91 (1.20–2.48)

3.47 (1.92–7.71)

0.020

PfRh4.2

22 (28.6%)

20 (27.8%)

74 (64.4%)

0.001

2.62 (1.47–4.66)

2.34 (1.72–3.16)

2.21 (1.44–4.02)

0.678

PfRh2 2030

20 (26.0%)

16 (22.2%)

87 (75.7%)

< 0.001

1.35 (1.14–1.86)

1.62 (1.25–2.35)

4.74 (1.99–9.80)

 < 0.001

PfRh5

7 (9.1%)

14 (19.4%)

59 (51.3%)

< 0.001

1.15 (1.06–2.72)

1.63 (1.14–2.11)

2.29 (1.40–3.08)

0.011

PvAMA1

2 (2.6%)

3 (4.2%)

73 (63.5%)

< 0.001

1.19, 1.89

2.90 (1.25–3.28)

5.04 (2.32–14.26)

0.020

PvMSP10

28 (38.4%)

24 (33.3%)

94 (81.7%)

< 0.001

1.57 (1.29–2.11)

1.43 (1.19–2.93)

2.47 (1.45–4.06)

0.002

PvMSP119

2 (2.6%)

4 (5.6%)

58 (50.4%)

< 0.001

1.36, 2.14

1.61 (1.43–1.93)

2.18 (1.50–5.10)

0.218

PvMSP8

22 (28.6%)

28 (38.9%)

92 (80.0%)

< 0.001

1.83 (1.16–2.60)

1.75 (1.39–3.03)

2.02 (1.40–3.31)

0.164

  1. *Only seropositive individuals were included in the analysis of each antigen
  2. ^Chi-square test for trend for difference in the proportion of seropositive individuals across age categories ( 1–7 years; 8–17 years; ≥ 18 years)
  3. ¶Non-parametric test for trend for the difference in the magnitude of response in seropositive individuals across age categories (1–7 years; 8–17 years; ≥ 18 years)
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us